Nottingham University Business School, University of Nottingham, Jubilee Campus, Nottingham NG8 1BB, England, UK
Department of Industrial and Manufacturing Systems Engineering, University of MissouriColumbia, E3437 Engineering Building East, Columbia, MO 65211, USA
Graduate School of Policy Science, Mie Chukyo University, 1846 Kubo, Matsusaka, Mie, 515-8511 Japan
a r t i c l e in fo
abstract
Making decisions on strategic investments, such as early stage manufacturing technology (MT), is a
complicated task. Early stage technologies are usually costly, and surrounded by uncertainty. The
potential benets are often hard to quantify prior to implementation. Thus, how could managers make
good decisions in a high-risk, technically complex business when the information they need to make
those decisions comes largely from the project champions who are competing against one another for
resources? Traditionally, in this problem domain, decisions are made based upon gut-feeling and past
experience, sometimes with the support of some multi-criteria decision-support tools. The criteria
evaluation process is very subjective and relies heavily on managers experience, knowledge, as well as
intuition. Thus, the evaluation approach is often not effectively carried out as there is lack of visibility
and traceability in the decision making process. The impact of this scenario is that managers are not
condent that resources are being optimised and applied to a mixed portfolio of projects to maximise
benets. This paper proposes a marginal analysis directed branch and bound approach for evaluating
and selecting early stage manufacturing technology (MT) projects. A case study is used to demonstrate
the application of the proposed approach. Implications of the proposed approach to practitioners and
academia are discussed and future research outlined.
Crown Copyright & 2010 Published by Elsevier B.V. All rights reserved.
Keywords:
Decision support systems
Early stage technologies
Marginal analysis
Visualisation
1. Introduction
Many early stage manufacturing technologies (MT) are of
strategic importance and may create future competitive opportunities. It is a challenge for manager to clarify the right
manufacturing technology alternatives as the number of technologies is increasing and the technology are becoming more and
more complex (Torkkeli and Tuominen, 2002; Shehabuddeen
et al., 2006). Therefore, managers need better methods that can
evaluate the strategic value of MT investment when the future is
uncertain (Auerswald et al., 2005). This paper denes early stage
as the early development of fundamental manufacturing processes or technologies.
Many researchers have developed approaches to support
technology evaluation and selection. The evaluation and selection
procedures have attracted the interest of a range of different tools
and techniques (Branke et al., 2007). Several common elements
were apparent, Henriksen and Traynor (1999) categorizes
these methods and techniques into the following categories:
Corresponding author.
E-mail addresses: kim.tan@nottingham.ac.uk (K.H. Tan),
NobleJ@missouri.edu (J. Noble), ysatoh@mie-chukyo-u.ac.jp (Y. Sato),
lixykt@nottingham.ac.uk (Y.K. Tse).
0925-5273/$ - see front matter Crown Copyright & 2010 Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.ijpe.2010.09.027
16
17
Selection
Criteria
Risk
Financial
Strategy
HSE
+0.1
Supply Security
Quality
+0.2
-0.2
Importance
Deployment
Novelty
IP Potential
Customer
Fig. 1. A technology selection decision path.
Branching
Bounding
Criteria 1
MT3
MT1
MT4
MT2
MT
Alternatives
MT4
MT2
MT1
MT3
MT
Ranked
Alternatives
Criteria 2
Performance
Analysis
Marginal
Analysis
Decision
Criteria n
Justification
Table 1
Primary decision criteria.
Criteria priority rank
Alt 1
Alt 2
1st
2nd
3rd
4th
Flexibility
Compatibility
Cost
Vendor
45
47
23
16
67
60
45
50
18
Table 2
Marginal analysis on Alt 1 and 2.
Flexibility
Compatibility
Cost
Vendor
Table 5
Marginal analysis on Alt 4 and Alt 3.
Alt 1
Alt 2
Alt 2 vs Alt 1
45
23
67
45
47
16
60
50
4.4%
30.4%
10.4%
11.1%
Ok
Not acceptable
Not acceptable
Good
Reject Alt 2
Table 3
Other alternatives.
Criteria
priority rank
Alt 3
Alt 4
Alt 5
Alt 4 vs Alt 3
48
30
66
46
4.0%
0.0%
1.5%
4.2%
Concern
Ok
Concern
Reject Alt4
Table 6
Marginal Analysis on Alt 5 and Alt 3.
1st
2nd
3rd
4th
Flexibility
Compatibility
Cost
Vendor
50
48
55
30
30
30
65
66
66
48
46
55
Table 4
Marginal analysis on Alt 3 and Alt 1.
Flexibility
Compatibility
Cost
Vendor
Flexibility
Compatibility
Cost
Vendor
Alt 4
Alt 3
Alt 3 vs Alt 1
50
30
65
48
11.1%
30.4%
3.0%
6.7%
Good
Good
Concern
Ok
Accept Alt 3
Flexibility
Compatibility
Cost
Vendor
Alt 5
Alt 5 vs Alt 3
55
30
66
55
14.6%
0.0%
1.5%
14.6%
Good
Good
Ok
Good
Accept Alt 5
4. Case study
A case study conducted by Tan et al. (2006) is used to further
illustrate the applicability of the proposed marginal analysis
approach. The case was conducted in Company Pharma, a worldleading manufacturer in the pharmaceutical industry. Traditionally, prioritisation and funding decisions for proof of concept
proposals on signicant, large MT projects in Company Pharma
were mainly made by a central committee. The approach,
however, could lead to gaps in the consistency of decision
making. Decisions were reached mainly through consensus and
the criteria used by the committee members to evaluate a
proposal were not explicitly known and documented. In the
previous work, a hybrid intelligent decision support system is
developed for supporting managers in making timely and optimal
MT investment decision. The intelligent system adopts Fuzzy
ARTMAP (FAM) neural network modelling techniques for retrieving the historical evaluation results. FAM is employed to guide the
retrieval process of the adapted case (i.e. the MT investment
project prioritisation and evaluation) in the repository. For a full
description of the hybrid intelligent system decision mechanism,
please refer to authors former work (Tan, et al., 2006). However,
the intelligent system approach has a major drawback in decision
visibility, i.e., the pattern learning mechanisms and the retrieval
process are blackbox mechanisms. The decision makers of
Pharma cannot know why this decision is made, what factors they
are considering, and what trade-offs has been taken.
As a result, the management team was not condent that the
resources had been optimised, as the decision process is lack of
transparency and traceability. Thus, the marginal analysis
approach is proposed to direct the justication of MT investment
decision making. The visibility of decision making is improved by
providing a clear justication pathway in which each criteria
trade-offs are clearly illustrated to the committee members.
The following example illustrates how the marginal analysis
approach can be applied at the MT Concept Phase for Company
Pharma. Table 7 represents 10 candidate MT projects with their
19
Alt 1
Alt 2
Alt 3
Alt 4
Flexibility
45
4%
11%
-4%
15%
Compatibility
23
-30%
30%
0%
0%
Cost
67
-10%
-3%
2%
2%
Vendor
45
11%
6%
-4%
15%
Reject
Accept
Reject
Accept
Alt 5
Table 7
Set of candidate MT projects.
MT projects
Priority
Risk
1
2
3
4
5
6
7
8
9
10
63.4
64.3
72.9
54.9
69.4
40.4
55.2
40.1
31.7
40.6
44.8
52.8
59.2
34.4
44.8
44.8
30.4
12.0
22.4
67.2
respective Priority and Risk scores. The priority and risk scores are
determined in the evaluation module, which employs the FAM
techniques to access the criteria performance of each potential
MT project.
The marginal analysis approach involves a series of incremental priority and risk calculations, which are explained as
following:
20
+12
-32
-27
8
+73
-16
+84
Accept
+23
3
Consider
-273
Reject
6
-49 10
Table 8
Marginal analysis on priority and risk for 10 candidate MT projects.
MT projects
Priority
Risk
Incr.
priority (%)
Incr.
risk (%)
Incr. priority/Incr.
risk (%)
9
8
6
10
4
7
1
2
5
3
31.7
40.1
40.4
40.6
54.9
55.2
63.4
64.3
69.4
72.9
22.4
12.0
44.8
67.2
34.4
30.4
44.8
52.8
44.8
59.2
0
26.5
0.7
0.6
35.1
0.5
15.0
1.4
7.9
5.1
0
46.4
273.3
50.0
48.8
11.6
47.4
17.9
15.2
32.1
73
273
49
84
12
32
16
23
27
57
0.3
1
72
5
32
8
52
16
Action
Reject
Maybe
Reject
Reject
Yes
Yes
Maybe
Maybe
Yes
Maybe
Selection
Criteria
Risk
Financial
Strategy
Accepted Projects
HSE
P4
+0.1
P4
P7
P7
P1
P5
P1
P5
P5
P3
Supply
Quality
+0.0
-0.2
Importance
P8
Deployment
P2
Rejected Projects
Novelty
IP
Customer
Fig. 5. Illustrative decision path for technology selectionsecond phase.
Table 9
Sequence of conducting marginal analysis in pharma case study.
Sequence of conducting
marginal analysis
Criterion
1
2
3
4
5
6
7
8
9
10
11
Risk
Financial
Strategy
Health/Safety (HSE)
Supply
Quality
Importance
Deployment
Novelty
Intellectual property (IP)
Customer
21